1-4 of 4
P. Swerdlow
Close
Sort by
Journal Articles

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

E. Vichinsky, R. Fischer, Z. Pakbaz, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B.U. Mueller, L. Coïc, G. Forni, L. Abetz, J.F. Baladi, C. Ressayre-Djaffer, I. Gathmann, D. Alberti, P. Marks
Journal: Blood
Blood (2005) 106 (11): 2334.
https://doi.org/10.1182/blood.V106.11.2334.2334
Published: 2005
Journal Articles

Reversive Loss of Pulmonary Function Induced by Acute Chest Syndrome: A Report from the National Acute Chest Syndrome Study Group (NACSG).

Lynne Neumayr, MD, C. Morris, MD, A. Wen, MD, A. Earles, PNP, S. Robertson, M. Abboud, MD, S. Ballas, MD, I. Browning, MD, R. Bellevue, MD, C. Daeschner, III, MD, P. Groncy, MD, H.A. Hume, MD, R. Iyer, MD, L. McMahon, MD, M. Moncino, MD, E. Orringer, MD, P. Swerdlow, MD, P. Waldron15, MD, R. Ware, PhD, MD, E. Vichinsky, MD, National Acute Chest Study Group (NACSG)
Journal: Blood
Blood (2005) 106 (11): 315.
https://doi.org/10.1182/blood.V106.11.315.315
Published: 2005
Journal Articles

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

E. Vichinsky, R. Fischer, E. Fung, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B. U. Mueller, F. Bernaudin, G. L. Forni, C. Ressayre-Djaffer, I. Gathmann, J. Holland, D. Alberti, P. Marks
Journal: Blood
Blood (2005) 106 (11): 313.
https://doi.org/10.1182/blood.V106.11.313.313
Published: 2005
Journal Articles

Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells

K Bhalla, P Swerdlow, S Grant
Journal: Blood
Blood (1991) 78 (11): 2937–2944.
https://doi.org/10.1182/blood.V78.11.2937.2937
Published: 1991